IMPACT OF DRUG USE ON QUALITY OF LIFE IN FOLLOW UP PATIENTS OF ACUTE CORONARY SYNDROME IN A TERTIARY CARE TEACHING HOSPITAL IN EASTERN INDIA
Abstract
Introduction: Acute coronary syndrome (ACS) includes unstable angina, non-ST segment elevation myocardial infarction, and ST segment elevation myocardial infarction. Joint guidelines by American College of Cardiology (ACC) and American Heart Association (AHA) in 2007 suggest secondary drug prevention measures to be used in patients with ACS with aspirin, clopidogrel/prasugrel, ACE inhibitors/ ARBs, Statins, Beta blockers. This study is aimed to find out impact of drug use in quality of life of ACS patients during follow up period. Materials and methods: It was a prospective unicentric study done at the OPD of cardiology,R.G.Kar Medical college, Kolkata. All prescriptions issued to study subjects attending the cardiology clinic during 18 months period were intercepted after consultation. Pattern of drug use was noted. Patients were asked 21 questions of “Minnesota living with heart disease questionnaire†and scores were calculated in 3 visits of each patient. Impact of drug use was calculated. Results: 525 patients were included in study. aspirin was given in 100%, clopidogrel/prasugrel in 98.29%, ACEI/ARB in 87.43%, statins in 100%, beta blockers in 86.86%. Total 408 patients were given drugs from all 5 groups. There was overall significant satisfactory improvement with drug therapy. Prescription of all 5 drug groups had significant better outcome in quality of life score than prescription of less than 5 drug groups. Conclusion: Drugs from all these 5 groups should be given to all follow up patients of ACS, unless contraindicated as they significantly improve quality of life of the patients.
*- ACE- angiotensin converting enzyme, ARB- angiotensin receptor blocker.
Â
DOI
https://doi.org/10.22270/jddt.v4i2.779Published
Abstract Display: 509
PDF Downloads: 730 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

.